Mirvetuximab (Anti-FOLR1) is a chimeric monoclonal antibody of IgG1 subtype targeting FOLR1 (folate receptor 1). The antibody-drug conjugate (ADC) Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. This ADC drug is a conjugate that combines a monoclonal antibody Mirvetuximab, linker and microtubule inhibitor (DM4). This biosimilar antibody is used for research only. MW: 145.2 KD.
Product Details |
Species Reactivity | Human |
---|
Host/Isotype | Human IgG1 |
---|
Class | Monoclonal |
---|
Type | Recombinant Antibody |
---|
Immunogen | Human FOLR1 (folate receptor 1) |
---|
Clone | Mirvetuximab biosimilar |
---|
Conjugate | Unconjugated |
---|
Purity | 99% |
---|
Molecular Weight | 145.2 KD |
---|
Protein Concentration | 1mg/ml |
---|
Storage Condition | Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
---|
Storage Buffer | 100mM Pro-Ac, 20mM Arg-Ac, pH 5.0 |